Clinical trials: Platelet Aggregation Inhibitors
Coronary Artery Disease, Percutaneous Coronary Intervention
The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
This is a multi-center, randomized, double-blind, triple-dummy, parallel-controled, dose-exploration phase II trial. Patients with coronary atherosclerotic heart disease and planned percutaneous coronary intervention （PCI） will…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors
- Trial name
- NCT03599284
- Testing
- Vicagrel 5mg, Vicagrel 6mg, Vicagrel 7.5mg
- Where
- 27 sites in China
- Volunteers
- 279 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Platelet Aggregation Inhibitors, NSTEACS
Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation
To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients with acute coronary syndrome without ST-segment elevation…
- Trial name
- NCT00325390
- Testing
- clopidogrel (SR25990C)
- Where
- Japan
- Volunteers
- 800 people
- Sponsor
- Sanofi